The use of the orthotopic model to validate antivascular therapies for cancer

MONICA LOI¹, DANIELA DI PAOLO¹, PAMELA BECHERINI¹, ALESSIA ZORZOLI¹, PATRIZIA PERRI¹,
ROBERTA CAROSIO¹, MICHELE CILLI², DOMENICO RIBATTI², CHIARA BRIGNOLE¹, GABRIELLA PAGNAN¹,
MIRCO PONZONI¹,#,* and FABIO PASTORINO¹,#,*

¹Experimental Therapies Unit, Laboratory of Oncology, G. Gaslini Children’s Hospital, Genoa, ²Animal Research
Facility, National Cancer Institute, Genoa and ³Department of Human Anatomy and Histology, University of Bari, Italy

ABSTRACT The orthotopic model reproduces aspects of the tumour microenvironment and emulates a number of important biological features of cancer progression, angiogenesis, metastasis and resistance. Due to its parallels with human cancer, the model can be used to evaluate therapeutic responses to various therapies. This review outlines the importance of using the orthotopic implantation of tumour cells in mice models for evaluating the effectiveness of antivascular therapies.

KEY WORDS: orthotopic model, vascular disrupting agent, antivascular therapy, cancer

Tumour vasculature and antivascular therapies

A functioning and continuously expanding vascular network is essential for tumour development, growth, survival and metastasis (Hanahan and Folkman, 1996). Given its pivotal role in these processes, tumour vasculature is a highly attractive target in anticancer therapy. Compared with the vasculature in normal tissue, the tumour vasculature is strikingly disorganized and tortuous (Eberhard, 2000; Konerding, 2001; McDonald and Choyke, 2003), its wall is poorly developed, often with discontinuous endothelial-cell lining, has relatively poor investiture with vascular smooth muscle cells, poor connections between pericytes and endothelial cells (Dvorak, 1988; Eberhard, 2000; Hashizume, 2000; Kobayashi, 1993) and an irregular, structurally abnormal basement membrane (Baluk, 2003; Paku and Paweletz, 1991). Endothelial cells themselves are often irregularly shaped, forming an uneven luminal layer, with loose interconnections and focal intercellular openings (Hashizume, 2000). These features contribute to a high intrinsic vascular permeability of macromolecules into the vasculature (Dvorak, 1991; Jain, 1987) and the consequent development of high interstitial fluid pressure (Boucher, 1990), which is augmented by inadequate lymphatic drainage. Tumour vascular networks are chaotic, featuring complex branching patterns and lack of hierarchy (Gillies, 1999; Konerding, 1999; Less, 1991). Vessel diameters are irregular and lengths between branching points are often very long. The result is a high geometrical resistance to blood flow, that such as small decreases in perfusion pressure, which have little effect in normal tissues, can be catastrophic in tumours (Sevick and Jain, 1989). Capillary blood contains abnormally high levels of deoxygenated blood (Mueller-Klieser, 1981), which, combined with heterogeneous blood flow and large intercapillary distances, contributes to micro-regional hypoxia in tumours (Vaupel and Hockel, 2000). The tumour is also starved of nutrient, under acidic conditions (owing to lactate production from anaerobic glycolysis) and under oxidative stress (Brown and Bicknell, 2001; Toyokuni, 1995). In this environment, endothelial cells are strikingly different from those in a normal tissue. Differently from the quiescent health endothelium, the endothelium in tumours proliferates rapidly and contributes to active angiogenesis (Denekamp and Hsobson, 1982).

Moreover, the development of new vascular networks depends on tumour and surrounding cells that are in constant communication with the tumour microenvironment: a complicated unorganized tissue of various cell types, such as fibroblasts, pericytes, mesenchymal and hematopoietic cells, endothelial cells, immune cells and extracellular matrix molecules (Shojaei and Ferrara, 2008).

All these differences in the architecture and in the cellular and biochemical composition between normal and tumour blood vessels provide the rationale for specific antivascular therapies in cancer.

The pivotal role of tumour vasculature and the effects of its selective destruction were already highlighted in 1923, when Woglom suggested that a damage of the capillary system might be the most effective way to inhibit tumour growth (Woglom, 1923).

Abbreviations used in this paper: NB, Neuroblastoma; VDA, vascular disrupting agent.

*Address correspondence to: Mirco Ponzoni or Fabio Pastorino. Experimental Therapies Unit, Laboratory of Oncology, G. Gaslini Children’s Hospital, 16148-Genoa, Italy. Tel: +39-010-5636342. Fax: +39-010-3779820. e-mail: mircoponzoni@ospedale-gaslini.ge.it or fabiopastorino@ospedale-gaslini.ge.it

These Authors share the last co-authorship.

Final, author-corrected PDF published online: 27 July 2011.
Although the nature of tumour vascularization is complex, it has been the subject of intense research in the past few decades. Initially, Folkman’s seminal work in the early 1980s highlighted the importance of angiogenesis in cancer progression (Folkman, 1986; Folkman and Klagsbrun, 1987). His hypothesis, that tumour growth beyond a certain size requires new blood vessel formation, laid the foundation for anti-angiogenic strategies. Similarly, Denekamp and his colleagues developed the concept of tumour blood vessel stability, emphasizing the role of angiogenesis in sustaining tumour growth (Denekamp, 1980). These early findings have now led to the development of targeted therapies, particularly those that exploit the differences between tumour and normal vasculature.

One such approach is vascular targeting, which involves the selective destruction of tumour blood vessels. This is achieved by targeting the angiogenic process, which is essential for tumour growth and metastasis. Vascular targeting strategies can be divided into two main categories: small-molecule VDAs and ligand-based therapies (Siemann, 2002). Small-molecule VDAs, such as Combretastatin A-4P (CA4P), ZD6126, AVE8062, NPI2358, MN-029, and OX4503, are designed to disrupt the cytoskeleton of proliferating tumour endothelial cells (Galbraith, 2001). These drugs achieve their effects by interfering with the polymerization of tubulin, leading to the disassembly of the microtubule network and the subsequent collapse of tumour blood vessels.

Ligand-based VDAs, on the other hand, use a targeting agent to deliver the therapeutic agent specifically to the tumour vasculature. These agents can be antibodies, peptides, toxins, procoagulant or proapoptotic effectors, all of which target the tumour endothelium. Examples of such ligands include the flavonoids, which have been shown to have potent antivascular and antitumour effects (Baguley and Ching, 2002).

The VDAs approach involves the selective delivery of the therapeutic agent to the tumour vasculature. By targeting the tumour blood vessel network, these agents can provide a more effective delivery of the therapeutic agent to the tumour site. This selective delivery can lead to a higher concentration of the therapeutic agent at the tumour site, while minimizing toxicity to normal tissue. This selective delivery can also lead to increased efficacy and reduced side effects.

The development of VDAs has been driven by the need to find more effective cancer therapies. Conventional cancer therapies, such as chemotherapy and radiation, have limitations in their ability to target tumour vessels effectively. VDAs offer a promising alternative by selectively targeting the tumour vasculature. This selective targeting can lead to increased efficacy and reduced side effects, making VDAs a promising area of research in the field of cancer therapy.
vasculature, to toxins, pro-coagulant, and pro-apoptotic effector molecules to induce endothelial cell damage have also been explored (Siemann, 2004; Thorpe, 2004). One of the more promising approach reported for vascular targeting is the coupling of specific ligands, such as antibodies and peptides, to the external surface of liposomes encapsulating chemotherapeutic agents (Allen, 2002; Allen and Cullis, 2004; Pastorino, 2007).

Antigenic determinants selectively and constitutively expressed on or near the tumour neovasculature are of particular interest. Some of these determinants, including endoglin (Burrows, 1995; Seon, 2002), vascular endothelial growth factor (VEGF) receptors (Brekken and Thorpe, 2001; Veenendaal, 2002), \(\alpha_\beta_3\)-integrins (Arap, 1998; Brooks, 1994), the fibronectin EDB domain (Nilsson, 2001), the prostate-specific membrane antigen (Chang, 1999) and specific aminopeptidases (Arap, 1998; Marchio, 2004; Taylor, 1993) have been identified as targets for ligand-directed approaches involving VDAs. Preclinical investigations employing such ligand-directed VDAs have shown not only the homing of the therapeutic moieties to tumour vessels but also the selective destruction of tumour vasculature (Pastorino, 2003; Thorpe, 2004).

The orthotopic animal model

In the development of new and more effective antivascular agents, it is of notable importance to have model systems available that can mimic the tumour biology observed in patients and give accurate information about signalling networks involved in vascular maintenance.

The study of these clinically relevant parameters required the tumour populations to be placed in the appropriate organ environment, either as orthotopic primary tumour cell inoculum (with subsequent spontaneous metastasis) or as experimental metastasis into relevant organs after intravenously tumour cell injection. Studies have established that the expression of cellular properties required for acquiring both the primary and the metastatic (the ability to metastatize to and colonize the distant organs) phenotypes, are dependent on both intrinsic properties of the tumour cells and host factors, which can differ between tissues and organs (Talmadge, 2007).

Animal models, by definition, are an approximation of reality, and their use for studying and developing antivascular therapies is controversial (Talmadge, 2007).

Fidler (Fidler, 1990), demonstrated that the microenvironment of subcutaneously injected human tumours is radically different from the original milieu and therefore, despite of species differences, the corresponding mouse organ of tumour origin should more closely resemble the original microenvironment than the subcutaneous milieu. Although subcutaneous sites are easily accessible and allow rapid screening of new antitumour compounds, increasing evidence demonstrates that faithful reproduction of the tumour microenvironment and more predictive treatment responses occur with orthotopic tumour implantation, in which either tumour cells or tumour fragments (surgical orthotopic implantation) are implanted within the organ corresponding to the original human tumour site (Fidler, 1991; Hoffman, 1999; Killion, 1998).

To date, a large body of published studies on orthotopic systems suggest that the results are likely to better reflect the behaviour and the molecular features of tumour in patients. Orthotopic implantation allows rapid growth of local tumour and spreading of distant metastases and seems to recapitulate the morphology and the growth characteristics of clinical disease (Fidler, 1986; Fidler, 1991; Hoffman, 1999). Indeed, clinical observation have suggested that the organ environment can influence the response of tumour to chemotherapies (Fidler, 2002; Killion, 1998) and orthotopic models allow to obtain a vasculature network similar to that of patient being useful for antivascular drug discovery. Interestingly, the vasculature of the tumour tends to acquire characteristics similar to those of the host environment (Langenkamp and Molema, 2009). The neovasculature of a specific tumour type can be indeed drastically different in terms of vascular architecture, microvascular density (MVD), permeability, vessel distribution, and gene expression, when the same tumour is grown in different locations of the body (Langenkamp and Molema, 2009). For example, the microvasculature of human glioblastoma implanted subcutaneously in nude mice became extensively fenestrated, with a large population of caveolae and a relatively high permeability, similar to the host endothelium of the subcutaneous space (Roberts, 1998). In contrast, the same tumour implanted in the brain acquired a microvasculature that is considerably less fenestrated, resembling more closely the brain microvascular phenotype. Similarly, human renal carcinoma cells implanted orthotopically into the kidney of nude mice became highly vascularized, whereas the subcutaneously growing of the same tumour did not (Singh, 1994), and the vasculature of melanoma growing intracranially had an higher density, but a smaller diameter, than the vasculature found in subcutaneously growing tumours (Kashiwagi, 2005). Differential patterns of expression of angiogenic genes accompany, and are probably responsible for these host environment-induced differences in vascularization. Renal cell carcinoma growth in the kidney resulted in a higher expression of fibroblast growth factor-2 (FGF-2), compared with the same tumour growing subcutaneously (Singh, 1994). Likewise, the decrease in fenestration pattern and permeability in glioblastoma tumours growing in the brain, compared with those growing subcutaneously, was accompanied by an elevated expression of the receptors for VEGF, whereas expression of VEGF itself did not differ per tumour location (Roberts, 1998). Human ductal pancreatic adenocarcinoma grown in the pancreas of nude mice exhibited enhanced expression of VEGF with concomitant higher growth rate compared with subcutaneous tumours implanted in the abdominal wall (Tsuzuki, 2001). Colon cancer xenografts in their orthotopic location produced higher levels of interleukin-8, carcinoembryonic antigen, as well as multidrug resistance proteins, than their subcutaneously growing counterparts (Kitadai, 1995). In addition to influence angiogenic genes expression, the host microenvironment can also determine the functionality of genes. Number, nature, and level of active angiogenic genes in a tumour could determine the capacity to override the host-environment driven control of tumour vascular behaviour that is intricately controlled by the microenvironment, as elegantly demonstrated by Kwei and colleagues (Kwei, 2004).

All these data emphasize the importance of the tumour microenvironment and the active reciprocal communication between tumour cells and the microenvironment. This explains the need for appropriate preclinical animal models representing the clinical setting in which to evaluate novel antivascular therapies for cancer in the context of the specific tumour environment. In this regard, data from orthotopic tumour systems may give a better indication of the potential clinical activity of antivascular drugs.
In summary, the orthotopic implantation of tumour cells into mice is mandatory. The importance of the orthotopic environment for reproducing human tumour conditions has been indeed shown for colon (Thalheimer, 2006), renal (Naito, 1987), breast (Price, 1990), bladder (Dinney, 1995), prostate (Stephenson, 1992), pancreatic (Bruns, 1999), lung (Boehle, 2000), esophageal (Gros, 2009) carcinomas and in neuroectoderma-derived tumours, such as melanoma and neuroblastoma (Pastorino, 2003a; Pastorino, 2007).

**Targeting the tumour vasculature in vivo**

Here, we present an overview of some vascular-targeting studies performed in orthotopic animal models.

As mentioned above, small molecules VDAs act on pathophysiological differences between tumour and normal tissue endothelium to achieve selective occlusion of tumour vessels. Among these agents, the combretastatin A-4 (CA-4) is one of the most promising (Lin, 1988).

The anti-tumour effects of combretastatin A-4 and its prodrug, the more soluble sodium-phosphate salt (CA-4P) has been evaluated in orthotopic models of human colon adenocarcinoma (Grosios, 1999) in which tumour growth in the colon is often accompanied by formation of metastasis in other parts of the body (Cowen, 1995). The primary tumour as well as some of the metastatic deposits (including body wall, lymph nodes and kidney deposits) developed extensive vasculature, underlining the importance of using orthotopic model in antivascular therapeutic studies. Extensive haemorrhagic necrosis after treatments was observed in vascularized but not in avascular tumours in mice both at the primary and metastatic sites. This observation is the clearest evidence that a direct effect of these compounds on tumour vasculature is essential for anti-tumour activity in vivo.

The effect of CA-4 was also evaluated in combination with Oxi4503, the diphosphate prodrug of CA1P (Pettit, 1989) in an orthotopically transplanted human renal cell carcinoma xenograft model, by the vascular casting and the chord-length distribution techniques (Salmon, 2006a; Salmon, 2006b). The results illustrated the loss of tumour vasculature and induction of wide scale necrosis in the central regions of the tumour. Compared to the surrounding normal tissue a lower vascular density at the tumour periphery after treatment with either agent was seen, suggesting that

---

**A**

Orthotopic neuroblastoma model: injection in the adrenal gland  

**Fig. 1. Orthotopic implantation, expansion and evaluation.**  

(A) **NB orthotopic implantation procedure.** (1) After anaesthesia, mice are injected with NB cell lines, after laparatomy, in the left adrenal gland. (2) Comparison, by histological analysis, between normal and NB-injected adrenal glands 14 days after tumour challenge. The establishment of metastasis is observed in several organs from 21 to 35 days after cell injection.  

(B) **Evaluation of NB tumour growth inhibition by BLI**  

(1) Luciferase-transfected NB tumour cells are orthotopically implanted in mice on day 0 and had their tumours surgically resected on day 20. TVT-DOX treatment started at day 22. (2) Orthotopic expansion, achieved tumour resection, and response to TVT-DOX are visualized via a highly sensitive, cooled CCD camera mounted in a light-tight specimen box (IVIS; Xenogen). Animals are injected intraperitoneally with the substrate D-luciferin and are anesthetized with 1% to 3% isoflurane and placed onto a warmed stage inside a light-tight camera box, with continuous exposure to 1% to 2% isoflurane. Imaging times ranged from 1 s to 3 min depending on the tumour model and the desired time point. The level of bioluminescence is recorded as photons per second.
invading tumour cells increase the inter-vascular spacing between normal blood vessels located within this region.

Ligand-targeted VDAs bind selectively to components of tumour blood vessels, carrying the coupled agents to occlude the vessels. Therefore, ligand-directed VDAs are composed of targeting and effector moieties linked together, usually via chemical cross-linkers or peptide bonds (Thorpe, 2004). The targeting moiety is usually an antibody or a peptide directed against markers selectively up-regulated on tumour endothelial cells (Thorpe, 2004).

On this regard, a successful strategy was based on the use of monoclonal antibodies to phosphatidylserine (PS) (Ran, 2002). It has been found that PS exposure on vascular endothelial cells is induced by hypoxia/reoxygenation, acidity, as well as by the presence of thrombin, inflammatory cytokines, and reactive oxygen species. This suggests that stress conditions in the tumour microenvironment may be responsible for inducing PS exposure on viable endothelium (Ran and Thorpe, 2002). In 2005, Thorpe PE et al., (Ran, 2005) tested the use of PS as a potential drug target for breast cancer. By the identification of an immunoglobulin G monoclonal antibody, 3G4, that binds to phosphatidylserine, they evaluated its effect within orthotopic breast tumour models in SCID mice. A specific homing to tumour blood vessels and a selective vascular damage with reduction of tumour vascularity and plasma volume, as well as a delay in tumour growth and the development of necrosis were obtained.

Several techniques are being used to find novel markers that could aid the development of targeting moieties with increased tumour specificity over those currently available. One of the most promising techniques is the in vivo phage display library screening, in which vast numbers of phages, each expressing a different peptide, are injected into animals (Trepel, 2002) or terminally ill patients (Arap, 2002). A short time later, samples of tumour and normal tissues (used as control) are removed and phages that have localized into both tumour cells and tumour vasculature are recovered. Phage-contained peptides that confer specific binding are then identified (Trepel, 2002).

In vivo phage display-based studies allowed to identify several peptides such as the peptide containing the sequence RGD, an \( \alpha_5 \beta_1/\alpha_5 \beta_3 \) binding motif, that can bind to the tumour (neo)vasculature (Arap, 1998; Pasqualini, 1997). Moreover, systemic administration of phages into nude mice led to the selection of a novel tumour vasculature-homing phage carrying the sequence NGR (Arap, 1998), able to recognize the tumour isoform of aminopeptidase N (APN, CD13). Constitutively, APN is a membrane-bound metallopeptidase that plays multiple functions as a regulator of various hormones and cytokines, protein degradation, antigen presentation, cell proliferation, cell migration, and angiogenesis (Luan and Xu, 2007; Razak and Newland, 1992; Riemann, 1999). More recently, this technique allows the identification of the sequence C PreCES, specific for another aminopeptidase, the aminopeptidase A (APA), expressed on endothelial and perivascular tumour cells (Marchio, 2004).

Various compounds, including cytotoxic drugs, cytokines, anti-angiogenic agents, viral particles, fluorescent and contrast tracers, DNA complexes, and other biologic response modifiers have been coupled or synthetically added to NGR peptides in order to increase their vasculature-homing effects (Arap, 1998; Buehler, 2006; Corti and Ponzoni, 2004; Curnis, 2005; Curnis, 2000; Grifman, 2001; Pastorino, 2006; Pastorino, 2003a; Zarovni, 2004).

Recently, we showed that liposomes are attractive for targeting drugs and other effectors to tumour vasculature because they can carry large payloads. Using nanoparticles of doxorubicin (DOX) targeted to tumour endothelial cells by coupling the liposomes with peptides containing the NGR sequence, we evaluated their efficacy in orthotopic model of human neuroblastoma (Pastorino, 2003a). Specifically, mice were orthotopically injected in the capsule of the left adrenal gland and tumour growth was evaluated by histological analysis, as shown in Fig. 1A. NGR-targeted, doxorubicin-encapsulated, liposomes caused endothelial and tumour cells apoptosis, and showed antitumour and antimetastatic activity in neuroblastoma (Pastorino, 2003a). In a subsequent study, we evaluated the efficacy of clinical-grade formulation of NGR-peptide-targeted liposomal doxorubicin, TVT-DOX, in several murine orthotopic xenografts of doxorubicin resistant human cancer, including lung, ovarian, and neuroblastoma (Pastorino, 2008). In addition, in order to assess the effect of NGR-targeted liposomal DOX therapy in controlling minimal residual disease (MRD) and in helping to prevent tumour relapse, a new neuroblastoma model was set up to take advantage of new imaging techniques. In vivo bioluminescence imaging (BLI) is indeed a non-invasive assay for the detection of small numbers of cells, and it enables the quantification of tumour growth within internal organs (Edinger, 2003). Using a highly sensitive, cooled CCD camera mounted in a light-tight specimen box, the initial trafficking of the malignant cells through the body, and organ-specific homing and orthotopic expansion over time were readily visualized and quantified. We used a reporter gene that code for a bioluminescent marker to permanently label NB cell lines, and we monitored primary tumours and metastases growth following orthotopic implantation into mice. Fig. 1B shows resection of primary tumour and response to treatment with TVT-DOX. Treatment with TVT-DOX induced a partial arrest in primary tumour growth and an inhibition of MRD in treated mice. Moreover, TVT-DOX resulted in effectively killing angiogenic tumour blood vessels and, indirectly, the tumour cells that these vessels supported (Pastorino, 2008).

On the basis of the “marker heterogeneity” concept, pointed out by Kerbel et al., (Kerbel, 2001), tumours can modulate the markers they induce on the adjacent endothelia, giving rise to heterogeneity in the expression of tumour vessel markers. Thus, it has been assumed that the use of combinations of VDAs that recognize two, or more, differently regulated, tumour vessel markers could enhance the therapeutic effects.

Adalimumab targeting efficacy was evaluated in orthotopically-implanted tumour animal models by targeting both the endothelial cells (using a vascular endothelial growth factor receptor inhibitor, AEE788) and the pericytes (using STI571) (Lu, 2007). The combination therapy showed a significantly decrease in pericyte coverage with reduction of microvessel density and an enhanced endothelial cell apoptosis.

With the similar purpose, we examined neuroblastoma orthotopic tumours for the therapeutic efficacy of a novel, APA-targeted, liposomal formulation of DXR, alone and in combination with APN-targeted DXR-loaded liposomes. Results obtained from these experiments showed that the use of APA- and APN-targeted, DXR-entrapped, liposomes administered in combination, led to a significant increase in life span compared to each treatment administered separately, obtaining a strong enhanced anti-tumour effect and induction of endothelial cells apoptosis and decrease in pericyte coverage (Loi 2010).
Combination therapy involving vascular disrupting agents (VDAs)

VDAs selectively destroy the central region of tumours leaving a peripheral rim of survival tumour cells. This pattern of tumour cell killing is characteristic of vascular targeting agents (Thorpe, 2004; Thorpe, 2003).

It is thought that vascular targeting agents are most effective against vessels in the interior of the tumour because of the high interstitial pressure in these regions and the vascular architecture. Interstitial fluid pressure rises precipitously from the tumour periphery to the tumour centre (Boucher, 1990), such that an increase in vascular permeability at the tumour centre following treatment might be catastrophic, whereas it is tolerated at the periphery (Tozer, 2005). Small-calibre vessels are also more sensitive to shutdown than larger ones and the proportion of these is often far higher at the centre than at the periphery (Tozer, 1999). There is often a complex vascular plexus at the tumour periphery, compared with a much lower vascular density at the centre, so that in the event of extensive vascular damage, residual flow is likely to persist at the periphery rather than at the centre. For these reasons, cells in this rim of viable tumour tissue are likely to be highly proliferative and well nourished. These characteristics, coupled with the accessibility of the surviving tumour cells to systemically administered agents, make these cells susceptible to killing by conventional methods. Conversely, VDAs induce the destruction of large areas of the tumour interior and exhibit excellent activity against bulky disease (Landuyt, 2001; Siemann and Shi, 2003), which is typically resistant to conventional anticancer treatment.

Thus, combining VDAs with cytotoxic chemotherapy, radiation and antiangiogenic treatments would be expected to lead to additive or even synergistic antitumour activity.

This concept has been extensively tested in preclinical settings by using a variety of tumour models and small-molecule targeting agents. To date, combined-modality approaches involving VDAs have included antiangiogenic agents, chemotherapeutic agents, hyperthermia, and radiation (Siemann, 2002; Thorpe, 2004).

Since both the initiation of new vessel formation and the integrity of the existing blood vessel network are critical to the growth and survival of a tumour, such a double assault on the tumour vasculature would appear to be a highly logical approach. The targeting of the tumour vasculature with AIs and VDAs is indeed complementary and not redundant. Whereas the VDAs significantly reduced the viable tumour mass, the AIs impaired subsequent tumour regrowth by interfering with the re-establishment of the tumour blood vessel network.

The combination of two different targeting strategies was also investigated. Effect of the combination therapy was investigated using the monoclonal antibody 3G4, direct to PS, and chemotherapeutic agents, such as gemcitabine and docetaxel, in pancreatic and breast orthotopic models, respectively (Beck, 2006; Huang, 2005).

The effect of the combination of gemcitabine with 3G4 was significantly better than either therapy alone, suggesting that gemcitabine enhances 3G4 function, or vice versa (Beck, 2006). Similarly, Huang et al., reported that 3G4 enhanced the inhibitory effect of docetaxel on the growth of orthotopically-implanted breast tumour model, pointing out the conditions in the tumour microenvironment play an important role in docetaxel-induced exposure of anionic phospholipids on tumour vascular endothelium (Huang, 2005).

Recently, the murine anti-PS antibody, 2aG4, in combination with local irradiation, was used to treat established gliomas growing in the brains of syngeneic rats that exerts biological characteristics resembling those of human glioblastoma (He, 2009). It has been shown that 2aG4 treatment not only has an antivascular action when combined with irradiation in this model, but also enhances the immunogenicity of the tumour leading to immunologic control of residual tumour cells. Moreover, antivascular effects and antitumour effects were accompanied by the recruitment of host immune cells in tumour vasculature and the subsequent infiltration into the tumour interstitium, as shown also by other studies (Beck, 2006; Tozer, 2008).

To this regard, we evaluated a successful combination strategy in neuroblastoma model using liposomal formulations of DXR targeted against both tumour cells, via anti-GD₃ monoclonal antibodies, and against the tumour vasculature, via the NGR peptide (Pastorino, 2006). The anti-GD₃-targeted liposomes resulted in direct cell kill, including cytotoxicity against cells that were at the tumour periphery and were independent of the tumour vasculature, whereas NGR peptide-targeted liposomal doxorubicin binds to and killed angiogenic blood vessels and, indirectly, the tumour cells that these vessels supported, mainly in the tumour core. The results clearly showed that liposomes administered in a sequential manner were statistically more effective in inhibiting neuroblastoma tumour proliferation in mice compared with formulations given alone (Pastorino, 2003a; Pastorino, 2003b). In conclusion, our novel approach relies on the combination of two different targeting strategies: NGR peptide-targeted liposomal doxorubicin binds to and kills angiogenic blood vessels and, indirectly, the tumour cells that these vessels support; the anti-GD₃-targeted liposomes result in direct cell kill, including cytotoxicity against cells that are at the tumour periphery and are independent of the tumour vasculature. We believe that this combination approach is a promising one in the search for more effective and less toxic cancer treatments.

Conclusion

In this review we explained the importance of using the orthotopic implantation of tumour cells in mice models for evaluating the effectiveness of antivascular therapies.

Although the ideal tumour model does not exist, the best approach to select an animal model for testing drug efficacy is to design one that can better reflect the clinical behaviour and can give information about therapeutic efficacy of therapies. The orthotopic model reproducing the appropriate tumour microenvironment allows the emergence of the biological features of cancer progression, angiogenic process, metastatic phenotype, resistance and therapeutic response to therapies with similar patterns observed in human cancer and, for these reasons, appears appropriate for studying antivascular approaches.

Moreover, what is increasingly obvious is that only an extensive acquisition of experimental in vivo data will ultimately allow adequate interpretation of preclinical studies that can potentially be translated into promising clinical therapeutic regimens.

Acknowledgements

We thank Ambrilia Biopharma Inc for providing us with TVT-DOX. Work supported by Associazione Italiana Ricerca Cancro (IG and MFAG), Italian Ministry of Health.
References


Further Related Reading, published previously in the *Int. J. Dev. Biol.*

**The role of pericytes in angiogenesis**  
Domenico Ribatti, Beatrice Nico and Enrico Crivellato  
*Int. J. Dev. Biol.* (2011) 55: 261-268

**Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells**  
Ann Peters, Paul W. Burridge, Marina V. Pryzhkova, Michal A. Levine, Tea-Soon Park, Christopher Roxbury, Xuan Yuan, Bruno Péault and Elias T. Zambidis  
*Int. J. Dev. Biol.* (2010) 54: 965-990

**Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention**  
Suzanne A. Eccles  

**Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies**  
Alicia R. Folgueras, Alberto M. Pendás, Luis M. Sánchez and Carlos López-Otín  

**Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis**  
G Bergers, D Hanahan and L M Coussens  
*Int. J. Dev. Biol.* (1998) 42: 995-1002

**The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis**  
D Ribatti, A Vacca, L Roncali and F Dammacco  
*Int. J. Dev. Biol.* (1996) 40: 1189-1197

5 yr ISI Impact Factor (2009) = 3.253